[go: up one dir, main page]

ME00491B - Vakcina protiv bolesti zapadnog nila - Google Patents

Vakcina protiv bolesti zapadnog nila

Info

Publication number
ME00491B
ME00491B MEP-2008-784A MEP78408A ME00491B ME 00491 B ME00491 B ME 00491B ME P78408 A MEP78408 A ME P78408A ME 00491 B ME00491 B ME 00491B
Authority
ME
Montenegro
Prior art keywords
west nile
vaccine
provides
vaccine composition
disease
Prior art date
Application number
MEP-2008-784A
Other languages
English (en)
French (fr)
Inventor
Hsien-Jue Chu
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of ME00491B publication Critical patent/ME00491B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Prikazani pronalazak obezbeđuje sigurnu i efikasnu kompoziciju vakcine protiv virusne bolesti zapadnog Nila. Imunogeno aktivna komponenta virusazapadnog Nila ili plazmida DNK, pomoćne supstance kao što je ulje koje se matabolizuje i farmakološki prihvatljivog nosača je formulisana uimunizirajući vakcinu. Pronalazak takođe obezbeđuje postupak za sprečavanje ili ublažavanje bolesti zapadnog Nila, kao što je encefalitis kodekvida davanjem kompozicije vakcine koja je ovde izložena.
MEP-2008-784A 2001-07-27 2002-07-23 Vakcina protiv bolesti zapadnog nila ME00491B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30833401P 2001-07-27 2001-07-27
PCT/US2002/023447 WO2003061555A2 (en) 2001-07-27 2002-07-23 West nile vaccine

Publications (1)

Publication Number Publication Date
ME00491B true ME00491B (me) 2011-10-10

Family

ID=27613166

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-784A ME00491B (me) 2001-07-27 2002-07-23 Vakcina protiv bolesti zapadnog nila

Country Status (25)

Country Link
US (8) US7153513B2 (me)
EP (3) EP1427444B1 (me)
JP (2) JP4718778B2 (me)
KR (2) KR20090053967A (me)
CN (2) CN1273189C (me)
AU (1) AU2002365244B2 (me)
BE (1) BE2014C006I2 (me)
BR (1) BRPI0211492B1 (me)
CA (1) CA2452545C (me)
CY (1) CY2014010I2 (me)
DK (1) DK1427444T3 (me)
ES (1) ES2435095T3 (me)
FR (1) FR14C0016I2 (me)
HK (1) HK1066470A1 (me)
HR (1) HRP20040195B1 (me)
HU (2) HU228690B1 (me)
LU (1) LU92348I2 (me)
ME (1) ME00491B (me)
MX (1) MXPA04000680A (me)
NZ (3) NZ570270A (me)
PL (2) PL212212B1 (me)
PT (1) PT1427444E (me)
RS (1) RS53184B (me)
WO (1) WO2003061555A2 (me)
ZA (1) ZA200401596B (me)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
AU2002365244B2 (en) * 2001-07-27 2007-12-06 Zoetis Services Llc West nile vaccine
US7585621B2 (en) * 2003-09-09 2009-09-08 Idexx Laboratories, Inc. Detection of West Nile virus infection and vaccination
US7074555B2 (en) * 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US7482017B2 (en) 2004-09-09 2009-01-27 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
EP1863528A2 (en) * 2005-04-01 2007-12-12 Wyeth Use of wnv dna vaccine in combination with a conventional vaccine to overcome immunogen interference
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
ATE507242T1 (de) 2005-05-12 2011-05-15 Crucell Holland Bv Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
RU2436591C2 (ru) * 2005-06-24 2011-12-20 Интервет Интернэшнл Б.В. Инактивированные химерные вакцины и связанные с ними способы применения
ES2393406T3 (es) * 2005-10-19 2012-12-21 University Of Florida Research Foundation, Incorporated Virus de la gripe capaces de infectar a cánidos, usos de los mismos
EP1941033A2 (en) * 2005-10-20 2008-07-09 Wyeth a Corporation of the State of Delaware Compositions and methods for the treatment of canine influenza virus disease
WO2007094854A2 (en) * 2005-12-14 2007-08-23 The Board Of Regents Of The University Of Oklahoma Rna virus vaccines and methods
EA031202B1 (ru) 2006-06-06 2018-11-30 Янссен Вэксинс Энд Превеншн Б.В. Антитело человека, обладающее фагоцитарной активностью против стафилококков, и его применение
KR101225304B1 (ko) * 2007-11-06 2013-01-22 와이어쓰 엘엘씨 마이코플라스마 하이오뉴모니아에 비독성 항원보강된 살아있는 백신
WO2009143524A2 (en) 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion vaccines
US9642908B2 (en) * 2008-07-30 2017-05-09 University Of Kentucky Research Foundation Equine disease model for herpesvirus neurologic disease and uses thereof
MX2011002071A (es) 2008-08-29 2011-04-05 Boehringer Ingelheim Vetmed Vacuna para el virus del nilo occidental.
MX2012004133A (es) * 2009-10-07 2012-05-08 Wyeth Llc Composiciones que comprenden adyuvante, macrolido y antigeno proteico y procedimientos de uso de las mismas.
CA2829226C (en) 2011-03-14 2023-01-03 Boehringer Ingelheim Vetmedica, Inc. Equine rhinitis vaccine
CN103045544B (zh) * 2011-10-17 2015-01-14 华中农业大学 预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用
DK3542819T3 (da) * 2013-05-14 2021-09-20 Zoetis Services Llc Hidtil ukendte vaccinesammensætninger omfattende immunstimulerende oligonukleotider
US20160199482A1 (en) * 2013-09-05 2016-07-14 Zoetis Services Llc Hendra and nipah virus g glycoprotein immunogenic compositions
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
PL70842Y1 (pl) * 2017-08-25 2019-06-28 Gondek Lukasz Kuznia Mocy Urządzenie do regeneracji filtrów cząstek stałych i katalizatorów samochodowych
MX2021010343A (es) 2019-02-27 2022-01-18 Univ Rochester Vacuna para la influenza multivalente con virus vivo atenuado para la prevencion y el control del virus de la influenza equina (eiv) en caballos.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US308334A (en) 1884-11-18 Ladder
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US5741696A (en) * 1992-08-07 1998-04-21 Syntro Corporation Recombinant equine herpesviruses
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
DE69518316T2 (de) * 1994-05-10 2001-03-29 American Home Products Corp., Madison Modifizierter,verbesserter,lebender brsv impfstoff
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
IL139844A0 (en) 1998-06-04 2002-02-10 Us Gov Health & Human Serv Nucleic acid vaccines for prevention of flavivirus infection
AU2002211490A1 (en) * 2000-10-04 2002-04-15 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
WO2002068637A2 (en) 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
US20050048073A1 (en) 2001-02-28 2005-03-03 De Groot Anne S. Methods of determining west nile virus epitopes and method of using the same
US20030148261A1 (en) * 2001-03-12 2003-08-07 Erol Fikrig Compositions and methods comprising West Nile virus polypeptides
US20030104008A1 (en) * 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
FR2823222B1 (fr) * 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
AU2002365244B2 (en) * 2001-07-27 2007-12-06 Zoetis Services Llc West nile vaccine
AU2003263853A1 (en) 2002-08-16 2004-03-03 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens

Also Published As

Publication number Publication date
HUP0401606A2 (hu) 2004-11-29
RS53184B (en) 2014-06-30
FR14C0016I1 (me) 2014-03-28
EP1427444A4 (en) 2008-01-02
HRP20040195B1 (hr) 2014-07-18
US7445787B2 (en) 2008-11-04
US20070166325A1 (en) 2007-07-19
PL220846B1 (pl) 2016-01-29
WO2003061555A2 (en) 2003-07-31
CY2014010I2 (el) 2024-02-16
HU228690B1 (en) 2013-05-28
US7648706B2 (en) 2010-01-19
JP2011057692A (ja) 2011-03-24
FR14C0016I2 (fr) 2015-07-24
EP1427444A2 (en) 2004-06-16
EP1427444B1 (en) 2013-08-21
JP4718778B2 (ja) 2011-07-06
PL398575A1 (pl) 2012-06-18
EP2283858A2 (en) 2011-02-16
US20070231349A1 (en) 2007-10-04
ZA200401596B (en) 2005-07-27
HRP20040195A2 (en) 2004-08-31
EP2281572A1 (en) 2011-02-09
US20070166326A1 (en) 2007-07-19
KR20040028952A (ko) 2004-04-03
US7153513B2 (en) 2006-12-26
NZ553165A (en) 2008-09-26
HK1066470A1 (en) 2005-03-24
BRPI0211492B1 (pt) 2016-06-21
US7648705B2 (en) 2010-01-19
KR20090053967A (ko) 2009-05-28
US20070231350A1 (en) 2007-10-04
NZ531265A (en) 2008-08-29
ES2435095T3 (es) 2013-12-18
CN1935258B (zh) 2013-04-03
BR0211492A (pt) 2004-08-17
US20030091595A1 (en) 2003-05-15
MXPA04000680A (es) 2004-04-05
NZ570270A (en) 2010-08-27
WO2003061555A3 (en) 2004-04-15
YU8004A (sh) 2006-08-17
DK1427444T3 (da) 2013-11-04
PL212212B1 (pl) 2012-08-31
CA2452545A1 (en) 2003-07-31
PL368535A1 (en) 2005-04-04
HUP0401606A3 (en) 2005-02-28
BE2014C006I2 (me) 2021-02-04
JP2005515236A (ja) 2005-05-26
CA2452545C (en) 2015-06-09
CN1935258A (zh) 2007-03-28
LU92348I9 (me) 2019-01-02
EP2283858A3 (en) 2011-03-23
CN1273189C (zh) 2006-09-06
US20070166802A1 (en) 2007-07-19
CY2014010I1 (el) 2020-05-29
US20070166324A1 (en) 2007-07-19
US20070178119A1 (en) 2007-08-02
LU92348I2 (fr) 2014-09-22
CN1535157A (zh) 2004-10-06
PT1427444E (pt) 2013-11-19
AU2002365244B2 (en) 2007-12-06
HUS1300055I1 (hu) 2016-08-29

Similar Documents

Publication Publication Date Title
ME00491B (me) Vakcina protiv bolesti zapadnog nila
ATE377011T1 (de) Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
BR9911163A (pt) Formulação de vacina, formulação farmacêutica, vìrus atenuado de influenza, processos para vacinar um indivìduo, para prevenir uma doença infecciosa em um indivìduo, e, para tratar ou prevenir tumores em um indivìduo
AR036039A1 (es) Composicion de vacuna para el virus de la influenza
MA29406B1 (fr) Vaccin toxoide alpha de c. perfringens
BRPI0409068A (pt) composições farmacêuticas para inibidores de protease viral de hepatite c.
HK1083192A1 (en) West nile virus vaccine
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
Werzberger et al. Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years’ followup after the Monroe field trial of VAQTA®
EP1301208A4 (en) Vaccine
MY153290A (en) Multivalent avian influenza vaccines
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
Vodopija et al. Rabipur: a reliable vaccine for rabies protection
BR0112486A (pt) Poliproteìna, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição farmacêutica, e, método para imunizar um indivìduo contra hiv
CY1114624T1 (el) Εμβολιο δυτικου νειλου
CO5660272A2 (es) Vacunas bovinas con adyuvantes
PL348550A1 (en) Ibdv mutant, vaccine containing it for protecting poultry against a disease caused by ibdv and method of protecting poultry against such disease
WO2002096359A3 (en) Piperazine pentanamide hiv protease inhibitors
NO953311D0 (no) Anvendelse av anti-helmint-vaksiner ved kontroll av parasittsykdom i forbindelse med tap av naturlig immunitet
WO2002078717A3 (en) Compositions and methods for reducing rna virus pathogenicity
GB9929783D0 (en) Toscana virus nucleoprotein